PhaseWell Research

PhaseWell Research is a clinical research site company dedicated to advancing the future of medicine by bringing innovative clinical trials closer to the communities they serve. We own and partner with high-performing research sites across the U.S., ensuring patients have greater access to cutting-edge therapies while supporting sponsors with faster, high-quality trial execution.

Founded in 2024, PhaseWell Research is built on a foundation of trusted, well-established sites known for their clinical excellence. Our growing network includes renowned centers such as Renstar Medical Research and the Gabrail Cancer & Research Center, both recognized for decades of expertise and consistently delivering high-integrity trial results.

We offer end-to-end Phase I–IV clinical trial services across a range of therapeutic areas, with a current focus on oncology, CNS (central nervous system) disorders, cardiovascular/metabolic diseases, and dermatology. This breadth of expertise allows us to meet diverse sponsor needs with agility and precision.

With over 28 years of collective clinical research experience, a team of 70+ dedicated professionals, and access to a network of 10+ research locations nationwide, PhaseWell Research is uniquely positioned to accelerate study start-up, enhance patient recruitment and retention, and deliver data of the highest quality.

Our mission is clear: to make clinical trials more accessible, efficient, and impactful. We are driven by the urgent need for broader trial participation, faster enrollment, and uncompromising patient safety. Through streamlined site operations and deep healthcare partnerships, we help sponsors bring life-changing treatments to market, faster and more effectively.

PhaseWell Research proudly serves the life sciences industry, partnering with pharmaceutical companies, biotech firms, and clinical research organizations (CROs) to advance clinical development and improve patient outcomes.